Immunologic diseases

The first mouse monoclonal antibody specific for human CD3 was produced in 1979 and named orthoclone OKT3. Aside from its use in the laboratory, OKT3 became the first anti-CD3 antibody to be utilized in transplantation medicine, but its wider application was hampered by its immunogenic and mitogenic properties (reviewed in [6]). Consequently, humanized and engineered anti-CD3 antibodies were developed to circumvent these limitations (Table 1). Since T cells and the TCR are involved in many immunological diseases, it is not surprising that the application of CD3 antibodies is not restricted to the field of transplantation. For example, CD3 antibodies are tested in clinical studies of diseases such as autoimmune diabetes (type 1 diabetes), immune-mediated inflammatory arthritis and inflammatory bowel disease [7]. 

Just as TCM, all of the other complementary medicines work mainly in those areas where modern medicine can not produce remarkable or immediate efficacy, such as immunological disease, degenerative diseases, cancer, and mental disorders. Few people will seek alternative resolutions for diseases in which effective treatment is already available, even in the places where complementary medicine is very popular. 

Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases,... 

McCord CP Metal fume fever as an immunological disease. IndMed 29 101-106, 1960... 

Asthma and Immunological Diseases in Pregnancy and Early Infancy, edited by M. Schatz, R. S. Zeiger, and H. N. daman... 

Scott, J. S., Immunological diseases occurring in pregnancy. Proc. World Congr. Gynecol. Ohstet. 9th pp. 225-231 (1979). 

Systemic haematological diseases 10. Systemic immunological diseases... 

Tab. 32.3 PBC-assodated immunological diseases (with some references)...

Jorge, A.D., Esley, C., Ahumada, J. Family incidence of primary sclerosing cholangitis associated with immunologic disease. Endoscopy 1987 19 114-117... 

Because antibodies bind to antigens, their function is often to augment intrinsic clearance mechanisms as well as potentially exerting definitive therapeutic effects. It is not surprising, therefore, that the therapeutic targets for antibody therapy are extremely broad, ranging from antitumor therapy to specific immunological diseases, for example rheumatoid arthritis. 

Schwartz LB, Austen KF. The mast cell and mediators of immediate hypersensitivity. In Samter M, Talmage DW, Frank MM, et al, eds. Immunologic Diseases, 5th ed. Boston, Little, Brown, 1995. 

To the point, a safe and controlled infection restore the immunological disease less harmful to the organism, following the strange strategy of the minor injuries . 

---